共 50 条
- [31] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trialANNALS OF ONCOLOGY, 2023, 34 : S861 - S861Hong, G.Meng, X.Yang, X.Zhang, Z. Y.Xia, J.Chen, Y-F.Wu, T.Shan, Z.Fan, Q.Wang, F.
- [32] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498Jin, Shui-LingQiao, ShishiLi, Ren-FengZhang, WeijieHe, WeiSu, ChangLi, Lu-HaoPan, JieGuo, Wen-ZhiZong, Hong
- [33] Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)Cortellini, AlessioBrunetti, LeonardoDi Fazio, Giuseppina RitaGarbo, EdoardoPinato, David J.Naidoo, JarushkaKatz, ArturLoza, MonicaNeal, Joel W.Genova, CarloGettinger, ScottKim, So YeonJayakrishnan, RitujithEl Zarif, TalalRussano, MarcoPecci, FedericaDi Federico, AlessandroAwad, MarkAlessi, Joao, VMontrone, MicheleOwen, Dwight HallSignorelli, DiegoFidler, Mary JoLi, MingjiaCamerini, AndreaDe Giglio, AndreaYoung, LaurenVincenzi, BrunoMetro, GiulioPassiglia, FrancescoYendamuri, SaiGuida, AnnalisaGhidini, MicheleAwosika, Nichola O.Napolitano, AndreaFulgenzi, Claudia A. M.Grisanti, SalvatoreGrossi, FrancescoD'Incecco, ArmidaJosephides, EleniVan Hemelrijck, MiekeRusso, AlessandroGelibter, AlainSpinelli, GianpaoloVerrico, MonicaTomasik, BartlomiejGiusti, RaffaeleNewsom-Davis, ThomasBria, EmilioSebastian, Martin
- [34] First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17EUROPEAN JOURNAL OF CANCER, 2024, 200Mark, MichaelFroesch, PatriziaGysel, KatrinRothschild, Sacha I.Addeo, AlfredoAckermann, Christoph J.Chiquet, SabrinaSchneider, MartinaRibi, KarinMaranta, Angela FischerBastian, Saravon Moos, RogerJoerger, MarkusFrueh, Martin
- [35] DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)ANNALS OF ONCOLOGY, 2023, 34Li, H-S.Xu, H.Duan, J.Wang, Z.Zhong, J.Cui, Y-Y.Fang, Q.Lei, S-Y.Wang, Y.
- [36] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Meng, XiangruiYang, XiuliHong, Yong-GuiZhang, ZhiyeXia, JinChen, YunfangWu, TaoShan, Zheng-ZhengFan, QingxiaWang, Feng
- [37] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)Lopes, GilbertoWu, Yi-LongKudaba, IvetaKowalski, DariuszCho, Byoung ChulCastro, GilbertoSrimuninnimit, VichienBondarenko, IgorKubota, KaoruLubiniecki, Gregory M.Zhang, JinKush, Debra A.Mok, Tony
- [38] Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 367 - 367Li, NingDeng, Wen-YingMa, Yi-JieBie, Liang-YuZhang, ChiWei, ChenLuo, Suxia
- [39] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377Yang, XiuliMeng, XiangruiHong, Yong-GuiZhang, ZhiyeXia, JinWu, TaoChen, YunfangShan, Zheng-ZhengFan, QingxiaWang, Feng
- [40] Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Spigel, David R.Shum, Merrill KingmanSchneider, Jeffrey GaryJotte, Robert M.Eisenstein, Jennifer L.Bhanderi, Viralkumar K.Konduri, KartikHung, AnnieHozak, Rebecca R.Ferry, David RaymondGandhi, LeenaChao, Bo H.Rybkin, Igor I.